News

 NEWCASTLE UPON TYNE, UK, 24th March 2021. QuantuMDx today announces it has raised £11 million in its latest funding round. Proceeds will be used to complete manufacturing and commercial scale up

NEWCASTLE UPON TYNE, UK, 13 February 2021. QuantuMDx today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne. QuantuMDx has developed

NEWCASTLE UPON TYNE, UK, 7th February 2021. Statement from Jonathan O’Halloran, Chief Executive Officer, QuantuMDx: QuantuMDx welcomes the news from the Government announcing a drive to increase workplace testing in

Conclusions verify QuantuMDx’ previous analyses of test performance Results confirm this is one of the most sensitive tests on the market Fulfils the requirements of the MHRA’s Target Product Profile

NEWCASTLE UPON TYNE, UK, 21 January 2021. QuantuMDx today announces the appointment of Diran Guiliguian as Chief Commercial Officer. Diran has over a decade of experience working within world-leading diagnostic

NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new variant

NEWCASTLE UPON TYNE, UK, 17 December 2020. QuantuMDx today announced it has invested over £11 million to scale up production of its flagship diagnostic device, Q-POC™ and disposable test cassette, to mass

Our Head of Assay Feasibility, Dr John Tyson presented an e-poster at ECCVID last month – the ESCMID Conference on Coronavirus. The e-poster focuses on  the independent, multi centre, clinical performance

Title: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – design, analytical and multi-centre evaluation of clinical performance White paper overview: After completing the development of our SARS-CoV-2 RT-PCR Detection Assay, QuantuMDx undertook

QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. QuantuMDx has now registered the

QuantuMDx Group today announces the launch of its sensitive SARS-CoV-2 assay for laboratory use, which delivers a result in approximately 70 minutes. Working with British manufacturing partner Biofortuna Limited, QuantuMDx

QuantuMDx today announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition